Ashland Inc. reported third-quarter results for the three months ended June 30, 2026, with revenue of $497M and diluted EPS of $0.35, reflecting a year‑over‑year revenue increase and a swing to profit from the prior-year quarter driven largely by the absence of a goodwill impairment recorded in the year‑ago period.
Financial Highlights
- Revenue: $497M for Q3, up from $463M in the year‑ago quarter (7.3% YoY).
- Net income: $16M for Q3, versus a loss of $(742)M in the year‑ago quarter (turnaround driven by absence of prior‑year goodwill impairment).
- Diluted EPS: $0.35 for Q3, versus $(16.21) in the year‑ago quarter (+$16.56 YoY).
Business Highlights
- Sales rose modestly: Q3 sales $497M vs $463M a year earlier; nine‑month sales $1,365M vs $1,347M, supported by higher volumes and favorable FX.
- Geographic mix: 73% of sales were outside North America, with Europe and Asia Pacific contributing growth through volume and pricing.
- Product momentum: Strength in Life Sciences and Personal Care drove higher volumes, pricing realization, and growth in high‑value applications.
- Operations: A multi‑year manufacturing network optimization program is underway targeting $50–$55M in pre‑tax savings, with early savings already realized.
- Portfolio and restructuring: Portfolio optimization actions (including Avoca, Nutraceuticals, CMC/MC) are largely complete with modest EBITDA impact; restructuring is substantially complete.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.